在乳腺癌中,趋同和演变的免疫基因组路径通向免疫逃脱
Juan Blanco-Heredia1,2,3, Carla Anjos Souza1,2, Juan L Trincado4,5
1IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain.
Nature communications
|February 21, 2024
概括
乳腺癌中的瘤进化驱动治疗耐药性和免疫逃避. 基因组异质性和T细胞多样性丧失使得晚期癌症能够逃脱免疫控制.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 乳腺癌进展过程中瘤和免疫细胞之间的相互作用尚不清楚.
- 转移性三阴性乳腺癌 (TNBC) 在治疗和免疫反应方面存在独特的挑战.
研究的目的:
- 在乳腺癌进展过程中,描述瘤和免疫细胞之间的动态相互作用.
- 调查转移性TNBC中治疗耐药性和免疫逃避背后的分子机制.
主要方法:
- 从指数患者和转移性TNBC患者的队列中分析了多区域瘤和血液样本.
- 基因组表征,包括瘤异质性和分子钟的评估.
- T细胞受体 (TCR) 谱系分析和免疫细胞分析.
主要成果:
- 增加瘤基因组异质性和独特的分子时钟与治疗耐药性和免疫逃脱相关.
- 随着时间的推移,TCR曲目的多样性下降,这表明乳腺癌进展的趋同演变.
- 抗原呈现的缺陷和转移中的T细胞透率降低创造了一个免疫抑制的微环境.
结论:
- 乳腺癌的进展涉及瘤与免疫细胞相互作用的动态变化,这些变化反映了基因组的改变.
- 治疗策略必须解决瘤进化和免疫逃避,以有效治疗转移性疾病.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


